About Scala Biodesign
Scala Biodesign is a company based in Tel Aviv (Israel) founded in 2021 by Adi Goldenzweig and Ravit Netzer.. Scala Biodesign has raised $21.5 million across 2 funding rounds from investors including TLV Partners, Grove Ventures and Deep Insight. Scala Biodesign offers products and services including Protein Stability Platform, Enzyme Optimization Platform, and Antibody Humanization Platform. Scala Biodesign operates in a competitive market with competitors including Liberation Labs, NJ Bio, Shantani Proteome Analytics, Kinaxo Biotechnologies and Peplib, among others.
- Headquarter Tel Aviv, Israel
- Founders Adi Goldenzweig, Ravit Netzer
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$21.5 M (USD)
in 2 rounds
-
Latest Funding Round
$16 M (USD), Series A
Mar 31, 2026
-
Investors
TLV Partners
& 3 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Scala Biodesign
Scala Biodesign offers a comprehensive portfolio of products and services, including Protein Stability Platform, Enzyme Optimization Platform, and Antibody Humanization Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Improves protein stability for therapeutic and industrial use
Enhances enzyme activity and specificity for manufacturing
Optimizes antibodies for stability and therapeutic applications
Unlock access to complete
Funding Insights of Scala Biodesign
Scala Biodesign has successfully raised a total of $21.5M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $16 million completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $16.0M
-
First Round
First Round
(11 Sep 2023)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2026 | Amount | Series A - Scala Biodesign | Valuation | Grove Ventures | |
| Sep, 2023 | Amount | Seed - Scala Biodesign | Valuation | TLV Partners |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Scala Biodesign
Scala Biodesign has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include TLV Partners, Grove Ventures and Deep Insight. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
VC firm investing in early stage startups in Israel & the US
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Scala Biodesign
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Scala Biodesign
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Scala Biodesign Comparisons
Competitors of Scala Biodesign
Scala Biodesign operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Liberation Labs, NJ Bio, Shantani Proteome Analytics, Kinaxo Biotechnologies and Peplib, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Fermentation products are manufactured and commercialized via CRO services.
|
|
| domain | founded_year | HQ Location |
Clinical development services are provided for biotechnology applications.
|
|
| domain | founded_year | HQ Location |
Drug discovery services are delivered via chemical-proteomics technologies.
|
|
| domain | founded_year | HQ Location |
Chemical proteomics for cellular target profiling and drug discovery services
|
|
| domain | founded_year | HQ Location |
Provider of peptide drug discovery and development services for global pharmaceutical industries
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Scala Biodesign
Frequently Asked Questions about Scala Biodesign
When was Scala Biodesign founded?
Scala Biodesign was founded in 2021 and raised its 1st funding round 2 years after it was founded.
Where is Scala Biodesign located?
Scala Biodesign is headquartered in Tel Aviv, Israel.
Who is the current CEO of Scala Biodesign?
Ravit Netzer is the current CEO of Scala Biodesign. They have also founded this company.
Is Scala Biodesign a funded company?
Scala Biodesign is a funded company, having raised a total of $21.5M across 2 funding rounds to date. The company's 1st funding round was a Seed of $5.5M, raised on Sep 11, 2023.
What does Scala Biodesign do?
Scala Biodesign was founded in 2021 in Tel Aviv, Israel, focusing on the biotechnology sector. Computational methods are utilized to create protein designs, with one-shot approaches employed to streamline processes and enhance efficiency. Services target acceleration of protein engineering for various applications, supported by a team including co-founders Adi Goldenzweig and Ravit Netzer as CEO. Operations emphasize scalable solutions for research and development needs.
Who are the top competitors of Scala Biodesign?
Scala Biodesign's top competitors include Liberation Labs, NJ Bio and Shantani Proteome Analytics.
What products or services does Scala Biodesign offer?
Scala Biodesign offers Protein Stability Platform, Enzyme Optimization Platform, and Antibody Humanization Platform.
Who are Scala Biodesign's investors?
Scala Biodesign has 4 investors. Key investors include TLV Partners, Grove Ventures, Deep Insight, and Innovation Israel.